小檗和水飞蓟固定剂量组合对成人血糖和胰岛素抵抗参数的疗效评估:随机对照试验的系统回顾和荟萃分析

IF 3.4 Q2 PHARMACOLOGY & PHARMACY Future Journal of Pharmaceutical Sciences Pub Date : 2024-02-27 DOI:10.1186/s43094-024-00603-7
Vishal Dubey, Jignesh Kansagra, Varun Sureja, Dharmeshkumar Kheni
{"title":"小檗和水飞蓟固定剂量组合对成人血糖和胰岛素抵抗参数的疗效评估:随机对照试验的系统回顾和荟萃分析","authors":"Vishal Dubey,&nbsp;Jignesh Kansagra,&nbsp;Varun Sureja,&nbsp;Dharmeshkumar Kheni","doi":"10.1186/s43094-024-00603-7","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Diabetes is one of the most prevalent metabolic diseases with high rate of morbidity and mortality. The increased level of blood glucose level and increased insulin resistance is the hallmark of diabetes. Currently, various non-pharmacological and pharmacological therapeutic options are used for lowering the glucose level and improving the insulin activity. The current systematic review and meta-analysis study was conducted to evaluate the efficacy of <i>Berberis aristata</i> and <i>Silybum marianum</i> fixed dose nutraceutical combination on serum glucose and glycated haemoglobin level and insulin resistance parameters.</p><h3>Main Body</h3><p>Randomized controlled trials, identified from three online databases, evaluating the efficacy of <i>Berberis aristata</i> and <i>Silybum marianum</i> fixed dose combination were identified and evaluated as per pre-defined protocol. Quality of studies was evaluated using PEDro scale, and risk of bias was assessed using Cochrane Risk of Bias Tool. Pooled effect was reported as mean difference (MD) and 95% confidence interval, while the complete study was conducted as per PRISMA and Cochrane guidelines. After complete literature screening and evaluation process, seven studies were included in the final analysis. Data of 825 participants (active group: 416 participants and control group: 409 participants) were utilized for the statistical analysis. All included studies (except one) were of good quality. Supplementation of fixed dose combination significantly reduced glucose level (MD: − 5.26 mg/dl; <i>p</i> = 0.02) and glycated haemoglobin (HbA1c) level (MD: − 0.69%; <i>p</i> &lt; 0.0001) as compared to control therapy, while greater insulin resistance reduction was observed in active group and the difference approached significance (MD: − 0.64 HOMA-IR score; <i>p</i> = 0.08). Risk of bias analysis revealed some concerns regarding biasness (mainly due to randomization, outcome measurement and selected reporting biasness). All included studies had moderate risk of biasness. Sensitivity analysis revealed effect of particular study on overall heterogeneity observed, while neither significant publication bias nor any missing study was observed.</p><h3>Conclusion</h3><p>The results of current study suggest that <i>B. aristata</i> and <i>S. marianum</i> fixed dose combination is effective in improving glycaemic and insulin parameters and can be effective in diabetic population. The observed sensitivity of certain studies on overall heterogeneity and the moderate risk of biasness warrants further well-designed clinical studies to strengthen the results of current study.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00603-7","citationCount":"0","resultStr":"{\"title\":\"Efficacy evaluation of Berberis aristata and Silybum marianum fixed dose combination on glycaemic and insulin resistance parameters in adult population: a systematic review and meta-analysis of randomized controlled trials\",\"authors\":\"Vishal Dubey,&nbsp;Jignesh Kansagra,&nbsp;Varun Sureja,&nbsp;Dharmeshkumar Kheni\",\"doi\":\"10.1186/s43094-024-00603-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Diabetes is one of the most prevalent metabolic diseases with high rate of morbidity and mortality. The increased level of blood glucose level and increased insulin resistance is the hallmark of diabetes. Currently, various non-pharmacological and pharmacological therapeutic options are used for lowering the glucose level and improving the insulin activity. The current systematic review and meta-analysis study was conducted to evaluate the efficacy of <i>Berberis aristata</i> and <i>Silybum marianum</i> fixed dose nutraceutical combination on serum glucose and glycated haemoglobin level and insulin resistance parameters.</p><h3>Main Body</h3><p>Randomized controlled trials, identified from three online databases, evaluating the efficacy of <i>Berberis aristata</i> and <i>Silybum marianum</i> fixed dose combination were identified and evaluated as per pre-defined protocol. Quality of studies was evaluated using PEDro scale, and risk of bias was assessed using Cochrane Risk of Bias Tool. Pooled effect was reported as mean difference (MD) and 95% confidence interval, while the complete study was conducted as per PRISMA and Cochrane guidelines. After complete literature screening and evaluation process, seven studies were included in the final analysis. Data of 825 participants (active group: 416 participants and control group: 409 participants) were utilized for the statistical analysis. All included studies (except one) were of good quality. Supplementation of fixed dose combination significantly reduced glucose level (MD: − 5.26 mg/dl; <i>p</i> = 0.02) and glycated haemoglobin (HbA1c) level (MD: − 0.69%; <i>p</i> &lt; 0.0001) as compared to control therapy, while greater insulin resistance reduction was observed in active group and the difference approached significance (MD: − 0.64 HOMA-IR score; <i>p</i> = 0.08). Risk of bias analysis revealed some concerns regarding biasness (mainly due to randomization, outcome measurement and selected reporting biasness). All included studies had moderate risk of biasness. Sensitivity analysis revealed effect of particular study on overall heterogeneity observed, while neither significant publication bias nor any missing study was observed.</p><h3>Conclusion</h3><p>The results of current study suggest that <i>B. aristata</i> and <i>S. marianum</i> fixed dose combination is effective in improving glycaemic and insulin parameters and can be effective in diabetic population. The observed sensitivity of certain studies on overall heterogeneity and the moderate risk of biasness warrants further well-designed clinical studies to strengthen the results of current study.</p></div>\",\"PeriodicalId\":577,\"journal\":{\"name\":\"Future Journal of Pharmaceutical Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-02-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00603-7\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s43094-024-00603-7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43094-024-00603-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景糖尿病是最常见的代谢性疾病之一,发病率和死亡率都很高。血糖水平升高和胰岛素抵抗增加是糖尿病的特征。目前,各种非药物疗法和药物疗法被用于降低血糖水平和改善胰岛素活性。本系统综述和荟萃分析研究旨在评估小檗和水飞蓟固定剂量营养保健品组合对血清葡萄糖和糖化血红蛋白水平以及胰岛素抵抗参数的疗效。正文从三个在线数据库中确定了评估小檗和水飞蓟固定剂量组合疗效的随机对照试验,并按照预定方案进行了评估。研究质量采用 PEDro 量表进行评估,偏倚风险采用 Cochrane 偏倚风险工具进行评估。汇总效应以平均差(MD)和 95% 置信区间的形式进行报告,而完整的研究则按照 PRISMA 和 Cochrane 指南进行。经过完整的文献筛选和评估过程后,有七项研究被纳入最终分析。统计分析采用了 825 名参与者(活动组:416 人,对照组:409 人)的数据。所有纳入的研究(一项除外)质量良好。与对照组相比,补充固定剂量的复合制剂可显著降低血糖水平(MD:- 5.26 mg/dl;p = 0.02)和糖化血红蛋白(HbA1c)水平(MD:- 0.69%;p < 0.0001),而积极组的胰岛素抵抗降低幅度更大,差异接近显著性(MD:- 0.64 HOMA-IR 评分;p = 0.08)。偏倚风险分析表明了一些有关偏倚的问题(主要是由于随机化、结果测量和选定报告的偏倚)。所有纳入的研究都存在中度偏倚风险。敏感性分析表明,特定研究对观察到的总体异质性有影响,但既未观察到明显的发表偏倚,也未观察到任何缺失的研究。结论目前的研究结果表明,B. aristata 和 S. marianum 固定剂量组合能有效改善血糖和胰岛素参数,对糖尿病人群有效。观察到某些研究对总体异质性的敏感性以及中度偏倚风险,因此需要进一步开展设计良好的临床研究,以加强当前研究的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Efficacy evaluation of Berberis aristata and Silybum marianum fixed dose combination on glycaemic and insulin resistance parameters in adult population: a systematic review and meta-analysis of randomized controlled trials

Background

Diabetes is one of the most prevalent metabolic diseases with high rate of morbidity and mortality. The increased level of blood glucose level and increased insulin resistance is the hallmark of diabetes. Currently, various non-pharmacological and pharmacological therapeutic options are used for lowering the glucose level and improving the insulin activity. The current systematic review and meta-analysis study was conducted to evaluate the efficacy of Berberis aristata and Silybum marianum fixed dose nutraceutical combination on serum glucose and glycated haemoglobin level and insulin resistance parameters.

Main Body

Randomized controlled trials, identified from three online databases, evaluating the efficacy of Berberis aristata and Silybum marianum fixed dose combination were identified and evaluated as per pre-defined protocol. Quality of studies was evaluated using PEDro scale, and risk of bias was assessed using Cochrane Risk of Bias Tool. Pooled effect was reported as mean difference (MD) and 95% confidence interval, while the complete study was conducted as per PRISMA and Cochrane guidelines. After complete literature screening and evaluation process, seven studies were included in the final analysis. Data of 825 participants (active group: 416 participants and control group: 409 participants) were utilized for the statistical analysis. All included studies (except one) were of good quality. Supplementation of fixed dose combination significantly reduced glucose level (MD: − 5.26 mg/dl; p = 0.02) and glycated haemoglobin (HbA1c) level (MD: − 0.69%; p < 0.0001) as compared to control therapy, while greater insulin resistance reduction was observed in active group and the difference approached significance (MD: − 0.64 HOMA-IR score; p = 0.08). Risk of bias analysis revealed some concerns regarding biasness (mainly due to randomization, outcome measurement and selected reporting biasness). All included studies had moderate risk of biasness. Sensitivity analysis revealed effect of particular study on overall heterogeneity observed, while neither significant publication bias nor any missing study was observed.

Conclusion

The results of current study suggest that B. aristata and S. marianum fixed dose combination is effective in improving glycaemic and insulin parameters and can be effective in diabetic population. The observed sensitivity of certain studies on overall heterogeneity and the moderate risk of biasness warrants further well-designed clinical studies to strengthen the results of current study.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
44
审稿时长
23 weeks
期刊介绍: Future Journal of Pharmaceutical Sciences (FJPS) is the official journal of the Future University in Egypt. It is a peer-reviewed, open access journal which publishes original research articles, review articles and case studies on all aspects of pharmaceutical sciences and technologies, pharmacy practice and related clinical aspects, and pharmacy education. The journal publishes articles covering developments in drug absorption and metabolism, pharmacokinetics and dynamics, drug delivery systems, drug targeting and nano-technology. It also covers development of new systems, methods and techniques in pharmacy education and practice. The scope of the journal also extends to cover advancements in toxicology, cell and molecular biology, biomedical research, clinical and pharmaceutical microbiology, pharmaceutical biotechnology, medicinal chemistry, phytochemistry and nutraceuticals.
期刊最新文献
Cubosomes: evolving platform for intranasal drug delivery of neurotherapeutics Carbapenem-resistant Acinetobacter baumannii infections among diabetic and non-diabetic patients and possible effective combination treatments Adenocarcinoma of unknown primary with TP53 gene polymorphism: a rare case report with literature review Design, synthesis and evaluation of new methyl piperazine derivatives as anticancer agents Solid self-nanoemulsifying drug delivery systems of nimodipine: development and evaluation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1